BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
Authors
Keywords
-
Journal
Journal of Oncology
Volume 2020, Issue -, Pages 1-7
Publisher
Hindawi Limited
Online
2020-09-08
DOI
10.1155/2020/4986365
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
- (2020) Veda N. Giri et al. JOURNAL OF CLINICAL ONCOLOGY
- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA2 and Other DDR Genes in Prostate Cancer
- (2019) Paz Nombela et al. Cancers
- 846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
- (2019) W Abida et al. ANNALS OF ONCOLOGY
- Genomics of lethal prostate cancer at diagnosis and castration resistance
- (2019) Joaquin Mateo et al. JOURNAL OF CLINICAL INVESTIGATION
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
- (2018) Emmanuel S. Antonarakis et al. EUROPEAN UROLOGY
- Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
- (2018) Joaquin Mateo et al. EUROPEAN UROLOGY
- Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
- (2018) Zafeiris Zafeiriou et al. EUROPEAN UROLOGY
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
- (2017) Matti Annala et al. EUROPEAN UROLOGY
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences
- (2016) Lawrence A. Loeb CANCER RESEARCH
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- Familial Risk and Heritability of Cancer Among Twins in Nordic Countries
- (2016) Lorelei A. Mucci et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
- (2015) S. Gillessen et al. ANNALS OF ONCOLOGY
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
- (2014) Elizabeth K. Bancroft et al. EUROPEAN UROLOGY
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
- (2014) Felix Dietlein et al. TRENDS IN GENETICS
- GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
- (2013) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response
- (2013) H. Christian Reinhardt et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The genetic epidemiology of prostate cancer and its clinical implications
- (2013) Rosalind Eeles et al. Nature Reviews Urology
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- The p53 network: cellular and systemic DNA damage responses in aging and cancer
- (2012) H. Christian Reinhardt et al. TRENDS IN GENETICS
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
- (2011) Z Kote-Jarai et al. BRITISH JOURNAL OF CANCER
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search